Core Viewpoint - Bright Minds Biosciences Inc. is launching a public offering of common shares and pre-funded warrants to raise aggregate gross proceeds of US$100 million to fund clinical trials and research initiatives [1][2]. Group 1: Offering Details - The public offering includes common shares and pre-funded warrants, with a total gross proceeds target of US$100 million [1]. - The company will grant underwriters a 30-day option to purchase up to an additional 15% of the common shares issued in the offering [1]. - The offering is being conducted under a shelf registration statement that was declared effective by the SEC on September 2, 2025 [3]. Group 2: Use of Proceeds - Net proceeds from the offering will be used to fund future clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome [2]. - The funds will also support the initiation of phase 1 clinical trials for BMB-105 and additional research and development for earlier phase programs [2]. Group 3: Company Overview - Bright Minds is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders [5]. - The company has a pipeline that includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical needs, such as epilepsy and depression [5][6]. - Bright Minds has developed a unique platform of highly selective serotonergic agonists, contributing to a rich portfolio of new chemical entity programs within neurology and psychiatry [6].

Core Viewpoint - Mobix Labs, Inc. plans to conduct a public offering of its common stock to raise funds for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The public offering will consist of shares of common stock or equivalents, all of which will be sold by the Company [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the terms [1]. - D. Boral Capital is acting as the Sole Placement Agent for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2]. Group 3: Regulatory Information - The securities are being offered under a "shelf" registration statement on Form S-3, which was declared effective by the SEC on January 24, 2025 [3]. - A preliminary prospectus supplement will be filed with the SEC and will be available on its website [3]. Group 4: Company Overview - Mobix Labs designs and sells components and systems for advanced connectivity solutions, including RF and EMI filtering technologies [5]. - The Company targets various markets such as defense, aerospace, commercial, and industrial sectors [5]. - Mobix Labs aims to enhance its product portfolio through acquisitions of companies with existing revenue and scalable technologies [5].

Core Viewpoint - AXT, Inc. has successfully closed its underwritten public offering, raising approximately $100 million through the sale of common stock at a price of $12.25 per share, including the full exercise of the underwriters' option to purchase additional shares [1] Group 1 - The company offered a total of 8,163,265 shares of common stock [1] - The underwriters exercised their option to purchase an additional 1,064,773 shares [1] - The total gross proceeds from the offering amounted to approximately $100 million [1]

Core Viewpoint - Society Pass Incorporated has announced a public offering of 1,500,000 shares at a price of $2.00 per share, aiming for gross proceeds of $3 million, expected to close on December 31, 2025 [1] Group 1: Offering Details - The public offering consists of 1,500,000 shares priced at $2.00 each, targeting gross proceeds of $3 million before expenses [1] - Rodman & Renshaw LLC is the exclusive placement agent for this offering [2] - The offering is conducted under a registration statement declared effective by the SEC on December 29, 2025 [3] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and general corporate purposes, including operating expenses and capital expenditures [2] Group 3: Company Overview - Society Pass was founded in 2018 and operates in Southeast Asia, focusing on e-commerce across Vietnam, Indonesia, Philippines, Singapore, and Thailand, which represent over 80% of the SEA population [5] - The company operates in three interconnected verticals: digital media, travel, and lifestyle, leveraging technology to enhance customer experience [5] - Society Pass went public in November 2021 and trades on Nasdaq under the ticker SOPA [6]

Core Viewpoint - Vision Marine Technologies Inc. has successfully closed a public offering of 32,000,000 units at a price of $0.30 per unit, generating gross proceeds of $9,600,000 before expenses [1]. Group 1: Offering Details - The offering consists of units that include one common share (or pre-funded warrant) and one-half of one warrant, with each whole warrant allowing the purchase of one common share at an exercise price of $0.375, expiring five years from issuance [1]. - ThinkEquity acted as the sole placement agent for this offering [2]. Group 2: Use of Proceeds - The proceeds from the offering will primarily be used for general corporate purposes, including inventory management, servicing floorplan lines of credit, general and administrative expenses, and prosecuting patent applications related to the E-Motion electric powertrain technology [2]. Group 3: Company Overview - Vision Marine Technologies is a leader in high-voltage electric marine propulsion systems and operates a multi-brand boat retail and service platform, providing premium boating experiences across both internal combustion and electric segments [3]. - The company offers an integrated ecosystem that spans propulsion, retail, service, and on-water consumer engagement through its E-Motion high-voltage propulsion platform and Nautical Ventures retail network [3].

Core Viewpoint - Aduro Clean Technologies Inc. has announced a public offering of common shares and warrants, aiming to raise approximately US$20 million to fund its clean technology initiatives [1][2]. Group 1: Offering Details - The offering consists of 1,739,130 common shares and accompanying warrants to purchase 869,565 common shares, with gross proceeds expected to be around US$20 million before expenses [1]. - Each whole warrant has an exercise price of US$16.00 per share, is immediately exercisable, and will expire three years from issuance [1]. - The underwriters have a 45-day over-allotment option to purchase an additional 260,869 common shares and/or warrants for 130,434 common shares [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the construction of a Demonstration-Scale Plant, ongoing research and development, general corporate purposes, and working capital [2]. Group 3: Regulatory Information - The offering is made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) and a Canadian short form base shelf prospectus [4]. - The final prospectus supplement detailing the terms will be filed with the relevant securities regulatory authorities [5]. Group 4: Company Overview - Aduro Clean Technologies specializes in patented water-based technologies for recycling waste plastics, converting heavy crude into lighter oil, and transforming renewable oils into higher-value fuels or chemicals [7]. - The company's Hydrochemolytic™ Technology utilizes water as a key agent in a low-temperature chemistry platform, aiming to convert low-value feedstocks into valuable resources for the 21st century [7].

Core Viewpoint - Aduro Clean Technologies Inc. has announced the pricing of its underwritten U.S. public offering, aiming to raise approximately US$20 million through the sale of common shares and accompanying warrants [1][2]. Group 1: Offering Details - The offering consists of 1,739,130 common shares and warrants to purchase 869,565 common shares, with gross proceeds expected to be around US$20 million before deductions [1]. - Each whole warrant has an exercise price of US$16.00 per share, is immediately exercisable, and will expire three years from the date of issuance [1]. - The underwriters have been granted a 45-day over-allotment option to purchase up to an additional 260,869 common shares and/or warrants for an additional 130,434 common shares [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for expenditures related to the construction of Aduro's Demonstration-Scale Plant, with any remaining funds allocated for ongoing research and development, general corporate purposes, and working capital [2]. Group 3: Regulatory Information - The offering is being made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) and a Canadian short form base shelf prospectus [4]. - The Base Shelf Prospectus has been filed with applicable securities commissions in Canada and the SEC, and is available for free on the respective websites [5]. Group 4: Company Overview - Aduro Clean Technologies specializes in developing patented water-based technologies for chemically recycling waste plastics, converting heavy crude and bitumen into lighter oil, and transforming renewable oils into higher-value fuels or chemicals [7]. - The company's Hydrochemolytic™ Technology utilizes water as a key agent in a low-temperature chemistry platform, aiming to convert low-value feedstocks into valuable resources for the 21st century [7].

Core Viewpoint - Cue Biopharma, Inc. has announced a public offering of 35,714,286 shares of common stock at a price of $0.28 per share, aiming to raise approximately $10 million in gross proceeds before expenses [1]. Group 1: Offering Details - The offering includes pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase an aggregate of 17,857,143 shares [1]. - Each common stock warrant will have an exercise price of $0.30 per share, will be exercisable immediately, and will expire five years from the date of issuance [1]. - The offering is expected to close on or about December 22, 2025, subject to customary closing conditions [1]. Group 2: Underwriters - H.C. Wainwright & Co. is acting as the sole book-running manager for the offering, while Newbridge Securities Corporation is serving as co-manager [2]. Group 3: Regulatory Information - The securities are being offered under an effective shelf registration statement on Form S-3 filed with the SEC on May 9, 2023, and declared effective on May 26, 2023 [3]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and can be accessed for free on the SEC's website [3]. Group 4: Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics to engage and modulate disease-specific T cells for autoimmune disease treatment [5]. - The company's proprietary platform, Immuno-STAT®, aims to harness the immune system's potential without broad systemic immune modulation [5]. - The company is headquartered in Boston, Massachusetts, and is led by a management team with expertise in immunology and protein engineering [6].

Core Viewpoint - Conavi Medical Corp. is conducting a public offering of common shares and pre-funded common share purchase warrants to raise between $15 million and $20 million for the development of its Novasight Hybrid system and general corporate purposes [2][3][4]. Offering Details - The offering consists of a minimum of 33,333,333 and a maximum of 44,444,444 securities priced at $0.45 per common share or $0.44999 per pre-funded warrant [3]. - Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.00001, with no expiration and can be exercised on a cashless basis [3]. Use of Proceeds - The net proceeds will be used to obtain US FDA 510(k) clearance for the Novasight Hybrid system, complete a limited market release, and initiate a broader commercial launch in the U.S. [4]. Closing and Regulatory Compliance - The offering is expected to close on or about December 23, 2025, subject to customary closing conditions and regulatory approvals [6]. - A final short form prospectus will be filed with securities regulatory authorities in Alberta, British Columbia, and Ontario [5]. Agent and Fees - The company will pay the agent a cash fee of 6.5% of the gross proceeds and grant compensation options equal to 6.5% of the total number of securities issued [7]. - A reduced cash commission of 3.25% will apply to certain purchasers on a president's list [7]. Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures, with its Novasight Hybrid system combining intravascular ultrasound and optical coherence tomography [12].

Core Viewpoint - Biodexa Pharmaceuticals PLC has announced a public offering priced at $10 million, aimed at funding its development programs and general corporate purposes [2][3]. Offering Details - The offering consists of 157,000 ADS Units, each comprising one American depositary share (representing 100,000 ordinary shares) and two Series L warrants [2]. - Additionally, there are 2,891,781 Pre-Funded Units, each consisting of one pre-funded warrant to purchase one ADS and two Series L Warrants [2]. - The public offering price for each ADS Unit is set at $3.28, while each Pre-Funded Unit is priced at $3.2799 [2]. Financial Proceeds - The expected gross proceeds from the offering, before deducting fees and expenses, are approximately $10 million [3]. - The net proceeds will be utilized for development programs, working capital, and other corporate purposes [3]. Closing and Agent Information - The offering is anticipated to close on December 19, 2025, pending customary closing conditions [4]. - Maxim Group LLC is acting as the sole placement agent for this offering [4]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs [7]. - The company's lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [7]. Product Details - eRapa is an oral formulation of rapamycin, an mTOR inhibitor involved in cellular metabolism and tumorigenesis [8]. - Tolimidone is a selective inhibitor of Lyn kinase, showing potential for glycaemic control in diabetes [9]. - MTX110 is a formulation of panobinostat designed for direct delivery to tumors, bypassing the blood-brain barrier [10][11].